title: Sorafenib induces partial response in metastatic medullary thyroid  carcinoma.
authors.affiliation: Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA. dudek002@umn.edu
authors.forename: Elena
authors.initials: E
authors.lastname: Spector
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Franklin
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Truskinovsky
authors.forename: Arkadiusz Z
authors.initials: AZ
authors.lastname: Dudek
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D018278:Carcinoma, Neuroendocrine / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000556:secondary; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D049268:Positron-Emission Tomography; D011725:Pyridines / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000150:complications; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib